10-K: BD Reports 8.2% Revenue Growth, Advances Strategic Portfolio Shifts

Becton, Dickinson and Company announced an 8.2% increase in worldwide revenues for fiscal year 2025, driven by strategic acquisitions and strong segment performance, while also detailing significant portfolio adjustments.

Summary

• Worldwide revenues for fiscal year 2025 increased by 8.2% to $21.840 billion, primarily driven by the acquisition of Advanced Patient Monitoring (4.8% impact) and volume/other increases (3.2% impact).
• Net income from continuing operations was $1.678 billion, with diluted earnings per share from continuing operations at $5.82.
• The Medical segment saw a 13.7% revenue increase, largely due to the Advanced Patient Monitoring acquisition and strong sales in Vascular Access Management and infusion systems.
• The Interventional segment grew revenues by 4.8%, fueled by advanced tissue regeneration, peripheral vascular disease products, and PureWick offerings.
• The Life Sciences segment experienced a slight revenue decline of 0.5% (0.6% FXN), primarily due to lower sales in Diagnostic Solutions and Biosciences instruments, partially offset by growth in Specimen Management.
• Approximately $1 billion of common stock was repurchased, and $1.196 billion in cash dividends were paid during fiscal year 2025.
• A definitive agreement was signed on July 13, 2025, to combine the Biosciences and Diagnostic Solutions business with Waters Corporation in a Reverse Morris Trust transaction, expected to close by the end of Q1 calendar year 2026.
• BD expects to receive a cash distribution of approximately $4 billion from the Waters transaction, with Waters assuming approximately $4 billion of incremental debt.
• The company is operating under an amended Consent Decree for its U.S. infusion pump business and received a Warning Letter for its Dispensing quality management system, accruing a $98 million liability as of September 30, 2025.
• An SEC investigation related to Alaris infusion pump reporting issues prior to 2021 was settled for $175 million in Q1 FY25.
• Approximately 6,905 product liability claims related to hernia repair devices and approximately 2,380 claims for implantable ports are ongoing, with a first trial for implantable ports scheduled for April 2026.
• A jury awarded $20 million in compensatory damages in an ethylene oxide lawsuit, with a $50 million punitive damages finding set aside due to a mistrial on specific intent, and appellate review accepted.

Sentiment

Score: 6

Explanation: BD demonstrates solid revenue growth, driven by strategic acquisitions and operational efficiencies, and is actively optimizing its portfolio through the planned Waters transaction. The company also maintains a strong commitment to shareholder returns via dividends and share repurchases. However, the slight decline in diluted EPS and cash flow from operations, coupled with significant ongoing legal and regulatory challenges (Consent Decree, FDA Warning Letters, product liability lawsuits, and the EtO litigation with a $20 million compensatory award), introduce considerable uncertainty and potential future liabilities. While management is addressing these issues, the ultimate financial impact remains unclear.

Positives

• Strong overall revenue growth of 8.2% in fiscal year 2025, reaching $21.840 billion.
• Successful integration and significant revenue contribution from the Advanced Patient Monitoring acquisition (4.8% of total revenue increase).
• Medical segment operating income as a percentage of revenues increased to 36.1% in 2025, reflecting lower manufacturing costs from continuous improvement and supply chain optimization.
• Interventional segment operating income as a percentage of revenues increased to 43.2%, also benefiting from lower manufacturing costs and productivity initiatives.
• Continued strong demand for key product lines such as Vascular Access Management, infusion systems, prefillable biologic solutions, advanced tissue regeneration, and PureWick offerings.
• Return of capital to shareholders through $1.196 billion in dividends and $1 billion in common stock repurchases in fiscal year 2025.
• Refinanced senior unsecured revolving credit facility, extending maturity to September 2030 and maintaining strong liquidity.
• Positive resolution of a shareholder derivative action and a DOJ investigation (FloChec and QuantaFlo devices) for immaterial amounts.
• Effective internal control over financial reporting as of September 30, 2025.
• Recognition as one of America's Most Innovative Companies, World's Best Companies, and World's Best Employers, reflecting strong human capital management and culture.

Negatives

• Diluted earnings per share from continuing operations slightly decreased to $5.82 in 2025 from $5.86 in 2024.
• Cash flows from continuing operating activities decreased to $3.430 billion in 2025 from $3.844 billion in 2024, primarily due to higher inventory and prepaid expenses, and lower accrued expenses.
• Life Sciences segment experienced a revenue decline of 0.5% (0.6% FXN), driven by lower sales of BD BACTEC blood culture products and Biosciences instruments.
• Negative pricing impact of 0.3% on worldwide revenues.
• Ongoing market dynamics in China, including volume-based procurement programs (VoBP), continue to negatively impact sales in Medical and Interventional segments.
• Lower market demand for certain Pharmaceutical Systems product categories and a decline in life science research funding impacting Biosciences.
• Higher interest expense in 2025 ($613 million) compared to 2024 ($528 million) due to increased total debt outstanding.
• Accrued a $98 million liability for estimated future costs related to the FDA Warning Letter for the Dispensing quality management system.
• A jury awarded $20 million in compensatory damages in an ethylene oxide lawsuit, with potential for a retrial on punitive damages.
• Unfavorable foreign currency translation impact on gross profit margin in Life Sciences.

Risks

• Global economic conditions, including inflation, capital market volatility, interest rate and currency rate fluctuations, and economic slowdown or recession, could adversely affect operations, demand, pricing, supply chain, and borrowing costs.
• International operations expose the company to commercial, political, and financial risks, including geopolitical conditions (Ukraine, Middle East, Asia), tariffs, sanctions, trade barriers, and changes in local healthcare systems.
• The medical technology industry is highly competitive, with rapid technological change, new entrants (including technology companies and low-cost manufacturers), and consolidation among healthcare providers, leading to pricing pressures.
• Market dynamics, changes in reimbursement practices, coverage policies, and third-party payer cost containment measures (e.g., competitive bidding, volume-based procurement programs) could affect demand and pricing for products.
• Reductions in customers' research budgets or government funding (e.g., U.S. National Institutes of Health) may adversely affect business, as seen in fiscal year 2025.
• Future growth is dependent on new product development, which requires significant investment and faces risks related to technological feasibility, clinical trials, regulatory approvals, intellectual property, and market acceptance.
• Foreign currency exchange rate fluctuations can affect reported revenue, assets, liabilities, and cash flows, and hedging activities may only partially offset these impacts.
• Inability to attract and retain key employees, particularly those with technical competencies, could lead to increased costs and operational disruptions.
• Cybersecurity incidents, breaches, or breakdowns of IT systems or infrastructure (including third-party vendors and emerging AI technologies) could result in regulatory inquiries, litigation, increased costs, reputational damage, lost revenue, fines, manufacturing challenges, and patient safety concerns.
• The development, deployment, and use of AI introduce new risks related to confidentiality, privacy, data protection, cybersecurity, intellectual property, legal liability, operational challenges, and reputational harm.
• Reduction or interruption in the supply of sole-sourced raw materials and components (e.g., plastics, glass, metals, oil-based resins) due to supplier issues, transportation delays, geopolitical developments, or regulatory actions could adversely affect manufacturing and sales.
• Interruption of manufacturing or sterilization operations (e.g., due to system outages, natural disasters, regulatory requirements, labor disruptions, or ethylene oxide regulations) could result in lost revenues and damage to customer relationships.
• Cost volatility in raw materials, components, labor, duties, freight, and energy could negatively impact operating results, exacerbated by climate change regulations and sustainability efforts.
• Climate change and related sustainability efforts, or legal/regulatory measures to address them, could increase energy, conversion, and transportation costs, impact raw material availability, and lead to physical damage to facilities.
• Exposure to lawsuits, including class actions for alleged antitrust violations, federal securities laws, environmental and product liability claims (hernia repair, pelvic mesh, inferior vena cava filters, implantable ports, ethylene oxide), and government investigations, could have a material adverse effect on financial results and distract management.
• Extensive and evolving regulation by the FDA and foreign agencies, including stricter requirements (e.g., EU MDR, EU IVDR), can increase compliance costs, delay product approvals, and lead to enforcement actions, recalls, or sanctions.
• Defects or quality issues with products, unapproved use, or inadequate disclosure of risks can lead to injury, recalls, enforcement actions, product liability claims, and reputational damage.
• Dependence on patents and other intellectual property assets, which can be lost through expirations, legal challenges, governmental action, or competitors designing around them, potentially leading to loss of competitive advantage or significant legal fees.
• Inability to service all of the company's indebtedness, or refinance existing debt on favorable terms, could have a material adverse effect on the business.
• Agreements governing indebtedness impose restrictions (e.g., on incurring debt, liens, mergers, asset sales) and financial covenants, failure to comply with which could result in default and accelerated repayment.
• The proposed combination of the Biosciences and Diagnostic Solutions business with Waters Corporation may not be completed on the contemplated timeline or at all, leading to significant non-recurring costs and business disruptions.
• Failure to realize expected operational, financial, and strategic benefits from the Waters transaction, or the transaction not qualifying for tax-free treatment, could adversely affect the business.
• Risks associated with the tax-free qualification of the Embecta Corp. spin-off.
• Strategic acquisitions, investments, or alliances may not be successful due to integration challenges, improper valuation, or inability to assess business opportunities.
• Natural disasters, public health crises, war, terrorism, social/political unrest, labor disruptions, and international conflicts could disrupt business, decrease demand, affect manufacturing/distribution, or cause interruptions in the supply chain.
• Fluctuations in demand for products sold to pharmaceutical companies due to funding constraints, consolidation, or alternative therapies.
• Adverse media exposure or other publicity could damage reputation or demand for products.
• Market fluctuations affecting pension plan asset values and actuarial assumptions could require additional contributions or increase pension plan expense.
• Inability to obtain anticipated benefits from restructuring programs.

Future Outlook

BD expects tariffs to adversely impact operating expense for fiscal year 2026 and potentially beyond, primarily relating to products or components imported from countries across its global supply chain with limited mitigation opportunities. The company anticipates continued investments in research and development, strategic tuck-in acquisitions, geographic expansion, and new product programs to drive future revenue and profit growth. The combination of the Biosciences and Diagnostic Solutions business with Waters Corporation is expected to close around the end of the first quarter of calendar year 2026, subject to regulatory and shareholder approvals and other conditions. Remediation or replacement of BD Alaris Infusion System devices in the U.S. market is expected to be substantially complete over the next calendar year. The company does not anticipate any significant required contributions to its pension plans in fiscal year 2026.

Management Comments

• Our success depends upon our continued ability to identify, hire, develop, motivate and retain a talented, skilled and high-performing workforce with diverse backgrounds and experiences at all levels across our organization, worldwide, in the highly competitive medical technology industry.
• BD remains focused on delivering durable growth, creating shareholder value and making appropriate investments for the future.
• We strive to continually invest in our associates with the goal of being an employer of choice for our approximately 72,000 associates located in 61 countries.
• We believe our commitment to an inclusive workforce, coupled with our purpose and culture, allows us to better understand patient and customer needs and develop innovative technologies to meet those needs.
• We continue to monitor international trade policy-related developments to assess their potential impacts to our operations.

Industry Context

The medical technology industry is characterized by rapid technological advancements, increasing regulatory complexity, and intense competition from both established players and new entrants, including technology companies and low-cost manufacturers. There is a global trend towards healthcare cost containment, with governments and private payers implementing measures like competitive bidding, volume-based procurement, and value-based payment reforms. The shift of care from acute to non-acute settings and increased focus on chronic disease management are also influencing demand for products. Cybersecurity threats are escalating in frequency and sophistication, particularly with the adoption of AI, posing significant risks to data integrity and patient safety. Regulatory scrutiny on sterilization methods, such as ethylene oxide, is increasing, potentially impacting production costs and capacity. Consolidation among healthcare systems and providers is concentrating purchasing power, leading to downward pricing pressure for medical device suppliers.

Comparison to Industry Standards

• BD's 8.2% revenue growth in FY25, significantly boosted by the Advanced Patient Monitoring acquisition, indicates strong inorganic growth, which is common in the consolidating medical technology sector.
• The company's focus on "smart devices, robotics, analytics, and artificial intelligence" aligns with broader industry trends where competitors are also investing heavily in digital health and AI-driven solutions to improve care workflows and outcomes.
• The ongoing challenges with volume-based procurement (VoBP) in China and declining government research funding reflect a common pressure point for global medical technology companies operating in emerging markets and those reliant on academic/government research.
• The Consent Decree and FDA Warning Letters highlight the stringent regulatory environment faced by all medical device manufacturers, with compliance issues often leading to significant remediation costs and market disruptions, similar to challenges seen with other large players in the industry.
• BD's commitment to "continuous improvement projects, supply chain optimization and other productivity initiatives" to lower manufacturing costs is a standard practice for large, diversified medical technology companies aiming to maintain margins amidst pricing pressures and rising input costs.
• The proposed spin-off and merger of the Biosciences and Diagnostic Solutions business with Waters Corporation is a strategic portfolio optimization move, akin to other large healthcare conglomerates divesting non-core or lower-growth segments to focus on higher-growth areas, such as the recent spin-off of Embecta Corp.

Management Changes

Corporate Governance

Legal Proceedings

• Approximately 6,905 product liability claims involving hernia repair devices, with a settlement agreement in Q4 FY24 for the vast majority of existing litigation.
• Ongoing product liability claims involving pelvic mesh products (majority in New Jersey Superior Court) and inferior vena cava filter products (various jurisdictions).
• Approximately 2,380 product liability claims involving implantable ports, with the majority pending in an MDL in the U.S. District Court for the District of Arizona, and the first trial scheduled for April 2026.
• Ongoing civil investigation by the Department of Justice regarding certain CareFusion contracts with the Department of Veterans Affairs for Alaris and Pyxis devices.
• Ongoing civil investigation by the Department of Justice regarding Genesis container products.
• Approximately 405 lawsuits involving approximately 415 plaintiffs in Georgia alleging personal injury from ethylene oxide (EtO) exposure near company facilities. A jury awarded $20 million in compensatory damages in the first trial, but a $50 million punitive damages finding was set aside due to a mistrial on specific intent, with appellate review accepted.
• Resolution of a matter with the SEC for $175 million in Q1 FY25 relating to reporting issues involving BD Alaris infusion pumps prior to 2021.
• Resolution of a DOJ CID regarding FloChec and QuantaFlo devices for an immaterial amount in September 2025.
• Resolution of a shareholder derivative action for an immaterial amount in August 2025.
• Payment made in Q4 FY25 to settle obligations for calendar years 2015-2018 related to Italian government medical device payback legislation, at 25% of invoiced amounts.

Stakeholder Impact

• Shareholders: Potential for increased value through strategic portfolio optimization (Waters transaction), share repurchases, and dividends. Risk of dilution from future equity issuances. Exposure to litigation outcomes and regulatory penalties.
• Employees: Reorganization into new segments (Medical Essentials, Connected Care, BioPharma Systems, Interventional, Life Sciences) may lead to role changes or new opportunities. Continued investment in associate growth, development, and well-being. Risk of labor shortages and increased turnover in competitive markets.
• Customers: Continued focus on improving medication management, patient safety, infection prevention, and diagnostic capabilities. Potential for enhanced product offerings through acquisitions (Advanced Patient Monitoring) and innovation (AI-enabled tools). Risk of product supply interruptions due to supply chain issues or manufacturing/sterilization disruptions.
• Suppliers: Continued efforts to optimize supply chain and ensure continuity of supply, but reliance on sole-sourced materials and components creates risk of disruption and price volatility.
• Creditors: Total debt decreased slightly, and the company refinanced its credit facility, indicating stable financial management. However, ongoing legal liabilities and potential regulatory penalties could impact financial health.

Next Steps

• Complete the remediation or replacement of BD Alaris Infusion System devices in the U.S. market over the next calendar year.
• Close the combination of the Biosciences and Diagnostic Solutions business with Waters Corporation around the end of the first quarter of calendar year 2026, subject to regulatory and shareholder approvals.
• Continue to implement changes at facilities to comply with EPA's NESHAP requirements for ethylene oxide emissions by April 2028.
• Assess the impact and implement changes to comply with the EPA's Interim Registration Review Decision for Ethylene Oxide, with various mitigation measures becoming effective over the next several years.
• Continue to address the FDA Warning Letter for the Dispensing quality management system and execute remediation plans.
• Proceed with the first scheduled trial for implantable ports MDL in April 2026.
• Pursue appellate review in the Georgia EtO trial regarding the punitive damages mistrial.
• Evaluate the implications of the One Big Beautiful Bill Act (OBBBA) on U.S. tax laws.
• Continue to invest in research and development, strategic tuck-in acquisitions, geographic expansion, and new product programs.

Key Dates

Recommendation

BD demonstrates solid revenue growth, driven by strategic acquisitions and operational efficiencies, and is actively optimizing its portfolio through the planned Waters transaction. The company also maintains a strong commitment to shareholder returns via dividends and share repurchases. However, the slight decline in diluted EPS and cash flow from operations, coupled with significant ongoing legal and regulatory challenges (Consent Decree, FDA Warning Letters, product liability lawsuits, and the EtO litigation with a $20 million compensatory award), introduce considerable uncertainty and potential future liabilities. While management is addressing these issues, the ultimate financial impact remains unclear. Therefore, a "hold" recommendation is appropriate, suggesting investors monitor the resolution of these legal and regulatory matters and the successful execution of the Waters transaction before making further investment decisions.

Keywords

Medical Technology, SEC Filing, 10-K, Becton Dickinson, BDX, Financial Results, Revenue Growth, Acquisitions, Divestitures, Debt Securities, Product Liability, FDA Compliance, Cybersecurity, Ethylene Oxide, Capital Allocation, Share Repurchase, Corporate Governance, Life Sciences, Medical Devices, Healthcare